TrialBreast cancer research and treatment2017

A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.

José Baselga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.